Compare H2O America (HTO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Vertex Pharmaceuticals Incorporated — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 52.5× H2O America's market cap, and H2O America pays a 3.03% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HTO | VRTX | |
|---|---|---|
Market Cap | $2.43B | $127.55B |
Volume | 593,883 | 1,487,944 |
Sector | Utilities | Health |
52-Week High | $65.43 | $557.96 |
52-Week Low | $44.44 | $407.37 |
Typical Hold Time | 40 Days | 120 Days |
Enterprise Value | $4.22B | $121.68B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.48, up 0.86% with a bearish technical signal despite bullish oscillators. The company shows stable fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent Texas acquisitions signal growth strategy, though cash flow trends show heavy investment activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
HTO presents a compelling value opportunity with strong analyst support and strategic expansion, though execution risks from recent acquisitions and bearish technical indicators warrant caution. The stock's current discount to consensus target offers potential upside for patient investors willing to navigate near-term volatility.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
